Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients
- 44 Downloads
Thalassemia, as the most prevalent genetic blood disorder, has many associated comorbidities including low bone mass. We studied the comparative effectiveness of alendronate (AL) and zoledronic acid (ZOL) on bone mass improvement in transfusion-dependent thalassemia (TDT) patients a year after treatment. Three hundred seventy-five TDT patients with low bone mass were enrolled in this study. After a year of treatment with either AL or ZOL, a second bone mineral density (BMD) test was ordered to compare the effectiveness of the two aforementioned drugs. Body mass index (BMI), physical activity, sun exposure, and biochemical laboratory data were also considered as associated factors in this study. The BMD test of both groups was almost the same at the baseline and it increased comparably after a year of treatment with AL and ZOL. However, there was a significant difference in lumbar spine BMD delta Z score between both groups of female patients. ZOL was more effective in increasing the lumbar spine BMD of female patients. The choice of bisphosphonates therapy (oral versus parenteral) should be individually selected by considering patient’s preference, compliance and the physician’s decision. Given the longer administration interval, and TDT patients’ compliance issue, it is justified to recommend ZOL as the drug of choice for patients suffering from low bone mass.
KeywordsBone density Beta-thalassemia Alendronate Zoledronic acid
This study was produced as a part of Haleh Bozorgi doctoral thesis with the specified grant number of 15195 provided by Shiraz University of Medical Science. We thank Shirin Parand at the Hematology Research Center for preparation of the manuscript. The authors wish to thank Sara Dadashzadeh and Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.
Compliance with ethical standards
Conflict of interest
Omid Reza Zekavat, Mohamadreza Bordbar, Sezaneh Haghpanah, Forough Saki, Asghar Bazrafshan and Haleh Bozorgi declare that they have no conflict of interest.
- 1.Maheri A, Sadeghi R, Shojaeizadeh D, Tol A, Yaseri M, Ebrahimi M (2016) Associations between a healthpromoting lifestyle and quality of life among adults with beta-thalassemia major. Epidemiol Health 38Google Scholar
- 7.Gilfillan C, Strauss B, Rodda C, Bowden D, Kean A-M, Obaid M, Crawford B (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79:138–144. https://doi.org/10.1007/s00774-019-01003-1 CrossRefGoogle Scholar
- 9.Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E, Kanaka-Gantenbein C, Chrousos GP, Kattamis A (2018) The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and metaanalysis. Hormones 1–14Google Scholar
- 12.Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 85:1492–1497Google Scholar
- 14.Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, Yoo KH, Jung KS, Kim YK, Rhee CK (2017) Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis 12:2465–2475. https://doi.org/10.2147/copd.s141295 CrossRefGoogle Scholar
- 15.De Sanctis V, Soliman AT, Elsefdy H, Soliman N, Bedair E, Fiscina B, Kattamis C (2017) Bone disease in β thalassemia patients: past, present and future perspectives. MetabolismGoogle Scholar
- 19.Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly iv infusion of zoledronic acid 5 mg versus a once–weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250CrossRefGoogle Scholar
- 21.Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol 111:902–907Google Scholar
- 23.Shirani F, Shahriari-Ahmadi A, Arabi M, Asefi N (2015) Evaluation of alendronate efficacy on bone mineral density in thalassemic patients. Int J Hematol-Oncol Stem Cell Res 6:20–24Google Scholar
- 26.McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114:999–1007. https://doi.org/10.1097/AOG.0b013e3181bdce0a CrossRefGoogle Scholar
- 28.Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590CrossRefGoogle Scholar
- 30.Piscitelli P, Auriemma R, Neglia C, Migliore A (2014) Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. Eur Rev Med Pharmacol Sci 18:3788–3796Google Scholar